



DIASORIN ANNOUNCES COMPLETION OF THE ACQUISITION OF LUMINEX CORPORATION

Saluggia, July 14, 2021 - DiaSorin S.p.A. (“**DiaSorin**”; FTSE MIB: DIA) announces it has completed the acquisition of Luminex Corporation (“**Luminex**”; NASDAQ: LMNX) for a price of USD 37.00 per share that corresponds to a total equity value of approximately USD 1.8 billion.

Through the acquisition, DiaSorin will gain access to Luminex’s multiplexing technology and a portfolio that will strengthen its existing offering, while expanding the Group presence in the United States. Additionally, this deal will provide access to Luminex’s applications throughout the Life Science industry, supporting access to academic and scientific research, expanding engagement with biopharma companies, and increasing access to clinical multiplexing assays for future Value Based Care projects.

“The acquisition of Luminex represents an important step in the expansion strategy of DiaSorin. Today, we begin a new phase of our growth, that will position DiaSorin as a fully-fledged diagnostic and life science player, that can offer increasingly sophisticated solutions to customers worldwide, also via the integration of the multiplexing technology that Luminex has pioneered globally,” commented Carlo Rosa, CEO of DiaSorin. *“The future success of the diagnostics and life science sectors will be increasingly determined by the ability to innovate through cutting-edge technologies and solutions. This is the reason why we believe that Luminex is the perfect asset to boost our growth and to turn us into an even more competitive global company. Now, we have to start the process of cultural integration, in which the people of DiaSorin and Luminex will come together with their passion, resourcefulness and professionalism.”*

Details regarding the contractual terms of the transaction can be found in the press release of April 11, 2021.

For additional information, please contact:

INVESTOR RELATIONS CONTACTS

Riccardo Fava

Corporate Vice President Communication & Investor Relations

Tel: +39 0161.487988

riccardo.fava@diasorin.it

Emanuela Salvini

Investor Relator

Tel: +39 0161.487567

emanuela.salvini@diasorin.it

U.S. MEDIA CONTACTS

Mary K. Conway

Tel: +1 516.606.6545

MConway@MKCStrategies.com



The Diagnostic Specialist

PRESS RELEASE



About DiaSorin

Headquartered in Italy and listed at the Italian Stock Exchange in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field and is active since 2021 in the Life Science business. For over 50 years, the Company has been developing, producing and marketing reagent kits used by diagnostic laboratories worldwide.

The Group operates in 5 continents through 45 companies, 4 branches, 10 manufacturing facilities and 9 research and development centers. The extensive diagnostic testing and Life Science offer, made available through continuous investments in research, positions DiaSorin as the player with the broadest range of specialty tests available within the diagnostic market, and identifies the Group as the “Diagnostic Specialist”.

More info at www.diasoringroup.com